In a significant announcement, the Trump administration unveiled multiple agreements aimed at drastically lowering the prices of weight-loss drugs for Americans. The new deals with pharmaceutical giants Eli Lilly and Novo Nordisk could reduce the cost of certain obesity medications to as little as $149 per month. Additionally, Medicare is set to start covering some of these drugs, enhancing access for eligible patients. The initiative is seen as a response to rising obesity rates and aims to make effective weight-loss treatments more affordable. Prominent endorsements have poured in for the plan, with Mark Cuban expressing support for the cost cuts. However, some critics argue that Trump is taking credit for legislation previously passed without bipartisan support.